Phase 1 trial with uTREAT[®] in brain cancer patients
Latest Information Update: 28 Jan 2026
At a glance
- Drugs Gallium-68 NOTA AE105 (Primary)
- Indications Brain cancer; Glioblastoma
- Focus Adverse reactions
Most Recent Events
- 12 Jan 2026 According to Curasight media release, top-line data is expected in Q2 2026.
- 18 Dec 2025 According to Curasight media release, first patient has been dosed in this trial.
- 26 Nov 2025 According to Curasight media release, this trial is now open for patient enrollment and first patient dosing expected Q4 2025.